Neuronetics (STIM) Competitors

Neuronetics (NASDAQ:STIM) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Which has more volatility and risk, STIM or MDXG?

Neuronetics has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500.

Is STIM or MDXG more profitable?

MiMedx Group has a net margin of 11.40% compared to Neuronetics' net margin of -53.67%. MiMedx Group's return on equity of 22.70% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-53.67%	-174.15%	-38.41%
MiMedx Group	11.40%	22.70%	16.77%

Which has preferable valuation and earnings, STIM or MDXG?

MiMedx Group has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$89.45M	2.71	-$43.71M	-$1.31	-2.79
MiMedx Group	$348.88M	2.72	$42.42M	$0.27	23.78

Do analysts prefer STIM or MDXG?

Neuronetics currently has a consensus price target of $5.50, suggesting a potential upside of 50.27%. MiMedx Group has a consensus price target of $11.50, suggesting a potential upside of 79.13%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of STIM or MDXG?

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 8.7% of Neuronetics shares are held by company insiders. Comparatively, 1.7% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to STIM or MDXG?

In the previous week, MiMedx Group had 5 more articles in the media than Neuronetics. MarketBeat recorded 10 mentions for MiMedx Group and 5 mentions for Neuronetics. MiMedx Group's average media sentiment score of 0.78 beat Neuronetics' score of 0.46 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiMedx Group	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats Neuronetics on 13 of the 15 factors compared between the two stocks.